What is Affect?
Affect Therapeutics operates at the intersection of clinical psychology and advanced data science. The company provides a comprehensive virtual clinic accessible via smartphone, designed to transform the standard of care for substance use and mental health. Its proprietary platform utilizes an AI-driven clinical decision support system to facilitate real-time triage, personalized counseling, and medication management. By partnering with health systems and payers, Affect ensures that its evidence-based interventions are both scalable and affordable, effectively bridging the gap in access to high-quality behavioral health services. The company's model is specifically engineered to provide clinician insight coverage, ensuring that care delivery remains both personalized and clinically rigorous.
How much funding has Affect raised?
Affect has raised a total of $50M across 3 funding rounds:
Seed
$1M
Series A
$23M
Series B
$26M
Seed (2021): $1M with participation from AlleyCorp companies
Series A (2023): $23M led by ARTIS Ventures
Series B (2025): $26M supported by ARTIS Ventures, City Light Capital, LifeArc Ventures, and Allumia Ventures
Key Investors in Affect
ARTIS Ventures
Artis Ventures is a dedicated venture capital fund focused on Tech Bio+Health, investing in innovative data-driven life sciences companies that aim to enhance human health and wellness.
City Light Capital
City Light Capital is a venture capital firm that invests in early stage companies which provide not only strong financial returns, but also positive contributions to the company's world.
LifeArc Ventures
LifeArc Ventures invests in early-stage science-led companies, providing them with venture funding, scientific insight, and commercial support.
What's next for Affect?
With the successful closure of this major enterprise-level funding, Affect is well-positioned to expand its market footprint and enhance its technological infrastructure. The strategic focus will likely center on deepening its integration with existing healthcare networks and refining its AI-driven triage capabilities to improve patient outcomes at scale. As the digital health landscape continues to evolve, Affect's ability to demonstrate measurable clinical efficacy will be paramount in securing further partnerships with large-scale health systems. The company is expected to leverage this capital to broaden its reach, ensuring that its virtual care model becomes a standard component of modern behavioral health delivery, ultimately driving long-term value for both patients and institutional stakeholders.
See full Affect company page
